Today we announced that patient dosing has commenced in the Phase 1 clinical trial of SENTI-202, a potential first-in-class Logic Gated off-the-shelf CAR-NK investigational cell therapy for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia (AML). Learn more: https://bit.ly/3yhWWZW #celltherapy #AML #CARNK
Congratulations to the Senti team on this important milestone!
Congrats, Senti team!!!
Congratulations!
Developing impactful therapies against cancer and infectious diseases
6moVery exciting news! Congratulations to the present and past members of the team involved in the development of this promessing therapy.